Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 16/20 | 0.47 |
| ▸ | IL1B | P01584 | 9/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034386 | 0.86 | CNR1 (0.47) | P2RX7IL1BCNR2CNR1 | |
| SCHEMBL2041383 | 0.85 | P2RX7 (0.54) | P2RX7IL1BCNR2CNR1IDO1 | |
| SCHEMBL2037218 | 0.85 | P2RX7 (0.49) | P2RX7IL1BCNR2CNR1IDO1 | |
| SCHEMBL2036958 | 0.84 | P2RX7 (0.64) | P2RX7IL1B | |
| SCHEMBL2035535 | 0.84 | IDO1 (0.53) | P2RX7IL1BCNR2CNR1IDO1 | |
| SCHEMBL2036409 | 0.84 | P2RX7 (0.61) | P2RX7IL1BCNR2CNR1IDO1 | |
| SCHEMBL2034650 | 0.84 | P2RX7 (0.48) | P2RX7IL1BCNR2CNR1IDO1 | |
| SCHEMBL2034925 | 0.84 | P2RX7 (0.48) | P2RX7IL1BCNR2CNR1IDO1 | |
| SCHEMBL2035609 | 0.83 | P2RX7 (0.50) | P2RX7IL1BCNR2CNR1 | |
| SCHEMBL2034933 | 0.81 | IDO1 (0.48) | P2RX7IL1BCNR2CNR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | P2RX7 250/4885IL1B 2128/4885CNR2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.